Abstract Body

Background: CD4 cell count thresholds are a key parameter used for assessing antiretroviral therapy (ART) eligibility. Determining the rate of CD4 decline is important in estimating the impact of different CD4 thresholds for ART initiation and for establishing monitoring frequency for patients not eligible for ART. Few data are available on CD4 decline in HIV-infected patients in resource limited settings. We analyzed the rate of CD4 decline in ART-naive adults in Rwanda and assessed time to reaching ART eligibility as per 2010 and 2013 WHO guidelines. Methodology: We examined CD4 decline in HIV-infected patients >15 years with CD4>600 cells and at least one follow-up CD4 prior to ART initiation enrolled from 2005-2010 at 41 Rwandan health facilities supported by ICAP-Columbia University. CD4 decline in the first 24 months was estimated using mixed linear regression modeling. Competing risk estimators were used to assess time to reaching ART eligibility at CD4<350 or CD4<500, accounting for loss to follow-up, death and ART initiation as competing risks. Results: We analyzed data for 4,643 patients with a median age of 32.1 years [Interquartile range (IQR): 25.9-40.1], 73% female, 65% with WHO stage 1 at enrollment and median pre-ART follow-up time of 21.4 months. Median and mean CD4 at enrollment were 773.0 [IQR: 676-923] and 830.1 [IQR: 676-923], respectively. Mean CD4 counts were significantly lower among men (-38.6, 95%CI 25.1-52.1, p<.0001) and patients >40 years of age (-20.9, 95%CI 7.1-34.7, p<.01). The average CD4 decline over 24 months of follow-up was 5.3 cells/month (95%CI 5.0-5.6) and 63.6 cells by 12 months (95%CI 60.2-67.0). No significant difference was observed in the rate of CD4 decline for men compared to women, however patients >40 years of age had a CD4 decline of 10.8 more cells per year (95%CI 3.0-18.6, p<.01). By 24 months, 11.1% (95%CI 10.1-12.1%) of patients reached CD4<350 and 33.0% (95%CI 31.4-34.5%) reached CD4<500. Among patients with CD4 600-800 cells at enrollment, less than half (45.9%, 95%CI 43.7-48.1) reached CD4<500 and 15.0% (95%CI 13.3-16.4) reached CD4<350 in 24 months of follow-up. Conclusions: In this large cohort of ART-naive HIV patients from Rwanda with CD4>600 cells, average CD4 decline was estimated to be 63.6 cells/year, a very similar rate to that found in resource-rich settings. One third of patients reached ART eligibility within 24 months using current WHO guidelines of CD4<500 and only 11% reached CD4<350 cells as per 2010 WHO guidelines.